A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors - Leijen, S; Soetekouw, P; Jeffry Evans, T; Nicolson, M; Schellens, J; Learoyd, M; Grinsted, L; Zazulina, V; Pwint, T; Middleton, M (2011)